BrainsWay (BWAY) announced that the U.S. National Institutes of Health, NIH, has awarded a new grant – totaling approximately $2.5 million over five years – to a research team led by Principal Investigator Dr. Claudia Padula and Co-Investigator Dr. Michelle Madore of Stanford University and the Palo Alto Veterans Institute for Research. The funding will support a clinical study evaluating the mechanism of action and potential efficacy of an accelerated Deep Transcranial Magnetic Stimulation protocol using BrainsWay’s device to treat Alcohol Use Disorder, AUD.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BWAY:
- Brainsway’s Strategic Investments and Growth Potential Drive Buy Rating with $17 Price Target
- Brainsway’s Deep TMS Study: A New Hope for Alcohol Use Disorder
- BrainsWay Expands U.S. Investments with New Mental Health Partnerships
- Brainsway enters two minority stake investments in mental health providers
- BrainsWay Announces Cashless Exercise of Warrant by Valor